Journal of ophthalmic inflammation and infection · 2025
Subconjunctival dexamethasone implant (Ozurdex®) in the management of refractory Non-Infectious anterior scleritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ganbold Battuya, Nguyen Ba Trung, Hung Jia-Horung, Mobasserian Azadeh, Thng Zheng Xian, Ghoraba Hashem, Yavari Negin, Feky Dalia El, Yasar Cigdem, Saengsirinavin Aim-On, Zhang Xiaoyan, Anover Frances Andrea, Mohammadi S Saeed, Tuong Ngoc, Than Trong, Khatri Anadi, Elaraby Osama, Akhavanrezayat Amir, Gupta Ankur Sudhir, Yoo Woong Sun, Nguyen Quan Dong, Or Christopher
Аннотация
OBJECTIVE: To report a case series of non-infectious anterior scleritis resistant to multiple lines of conventional therapies which were eventually successfully treated with off-label subconjunctival dexamethasone implant (Ozurdex®) injection (SDI).
METHODS: A retrospective case series of 4 patients (6 eyes).
RESULTS: In the index case series, the patients had a mean age of 57.2 years (range 36 to 82 years, SD 19.2 years) with 50% being female. Two patients had underlying autoimmune diseases: rheumatoid arthritis (n = 1), and granulomatosis with polyangiitis (GPA) (n = 1). The other patients were diagnosed with idiopathic anterior scleritis after extensive systemic investigations (n = 2). The mean follow-up duration and the mean number of concomitant therapies prior to SDI was 27 (SD 17.7) months and 2 (SD 0.81), respectively. In all patients, symptom resolution and significant improvement in disease activity were achieved after SDI, persisting for an extended period following the resorption of the implant. No scleral melt, infection or ocular hypertension were noted following SDI.
CONCLUSION: SDI may be a safe and effective therapeutic option for resistant non-infectious anterior scleritis.
METHODS: A retrospective case series of 4 patients (6 eyes).
RESULTS: In the index case series, the patients had a mean age of 57.2 years (range 36 to 82 years, SD 19.2 years) with 50% being female. Two patients had underlying autoimmune diseases: rheumatoid arthritis (n = 1), and granulomatosis with polyangiitis (GPA) (n = 1). The other patients were diagnosed with idiopathic anterior scleritis after extensive systemic investigations (n = 2). The mean follow-up duration and the mean number of concomitant therapies prior to SDI was 27 (SD 17.7) months and 2 (SD 0.81), respectively. In all patients, symptom resolution and significant improvement in disease activity were achieved after SDI, persisting for an extended period following the resorption of the implant. No scleral melt, infection or ocular hypertension were noted following SDI.
CONCLUSION: SDI may be a safe and effective therapeutic option for resistant non-infectious anterior scleritis.